Patients who are prescribed higher daily doses of the medication buprenorphine for opioid use disorder are significantly more ...

Addressing overdoses from “street drugs” containing potent synthetic opioids poses a key challenge when utilizing opioid antagonists. A standard approach to known or suspected opioid overdose includes ...

Few patients with opioid toxicity receive opioid agonist therapy (OAT), data suggest. In a retrospective study that examined about 21,000 hospital visits related to opioid use disorder (OUD) in ...

Opioid agonist treatments (OATs) such as methadone and buprenorphine-naloxone are standard therapy for opioid use disorder, but treatment duration is decreasing as fentanyl becomes more prevalent in ...

Please provide your email address to receive an email when new articles are posted on . FDA recently approved Lybalvi for the treatment of schizophrenia and for use in manic and mixed (depressive and ...

Widespread access to opioid agonist treatment (OAT) can reduce the risk of suicide by 35% among people with opioid use disorder, according to a new study published in Addiction. Researchers led by the ...

While overall rates of opioid overdose in the state have decreased in recent years, data from the Washington Department of Health show rates in American Indian and Alaska Native communities continue ...